Inresa Drugs
Inresa Arzneimittel GmbH is a German pharmaceutical company that manufactures and distributes generic hospital injectables and licensed medical products to German hospitals and pharmacies under its own regulatory approval (§13 AMG).
- Company typePrivate
- Founded1993
- HeadquartersFreiburg Im Breisgau, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Inresa Drugs firmographics
Firmographics- Name
- Inresa Drugs
- Legal name
- Inresa Arzneimittel GmbH
- Website
- https://inresa.de
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inresa Arzneimittel GmbH is a German pharmaceutical company that manufactures and distributes generic hospital injectables and licensed medical products to German hospitals and pharmacies under its own regulatory approval (§13 AMG).
- Ownership category
- akta.pro rank
Inresa Drugs industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Sterile Injectable Generics (HLAIABAC)
- akta.pro secondary industries
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic Hospital & Institutional Products (HLAIABAL), Authorized Generics (HLAIABAK), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)
Keywords
Where Inresa Drugs is headquartered
LocationHeadquarters
- HQ city
- Freiburg Im Breisgau
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Inresa Drugs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others
Revenue model
- Generic pharmaceutical sales: Sale of generic pharmaceutical preparations under their own regulatory approval to hospitals in Germany. Products include injectables, IV solutions, and other hospital-grade medications.
- Licensed product distribution: Distribution of medical products and pharmaceuticals under license agreements with other pharmaceutical manufacturers.
- Single import services (§73.3 AMG): Individual import of medicines according to §73.3 AMG for German pharmacies, providing access to diverse range of compliant pharmaceutical products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Standard pharmaceutical products - price list available upon request |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Inresa Drugs product offering
Product offeringCore offering
Inresa Arzneimittel GmbH manufactures and distributes generic pharmaceutical preparations — primarily injectable and intravenous medications — under its own regulatory approval (manufacturing authorization per §13 AMG) to German hospitals. The company also distributes licensed medical products and pharmaceuticals from other manufacturers, and provides individual import services under §73.3 AMG for German pharmacies requiring access to medicines not otherwise available in Germany.
Product overview
Inresa Arzneimittel GmbH is a pharmaceutical company specializing in hospital supplies of generic preparations and licensed medical products. The product portfolio comprises injectable neuromuscular blocking agents (Pancuronium, Vecuronium, Rocuronium, Sugammadex), anaesthetics (Esketamin, Ketamin), antibiotics (Erythromycin i.v.), antifungals (Micafungin), and other hospital-critical medications including Terlipressin, Dexketoprofen, Somatostatin, and the formulation vehicle InOrpha. The company also offers individual import of medicines for German pharmacies under §73.3 AMG.
Differentiator
Problem solved
Functional benefit
Products and services
- Pancuronium Inresa Injection solution for intravenous (I.V.) administration, used as a neuromuscular blocking agent for hospital use.
- Esketamin Inresa 25 mg/ml (2 ml / 10 ml) Anaesthetic agent for intravenous or intramuscular application for hospital use.
- Ketamin Inresa 2 ml Anaesthetic for intravenous or intramuscular injection or infusion after dilution.
- Erythromycin Inresa i.v. 1 g Antibiotic preparation for intravenous infusion, supplied to hospitals.
- Micafungin Inresa 50 mg & 100 mg Antifungal agent for intravenous application after reconstitution and dilution.
- Vecuronium Inresa 10 mg Neuromuscular blocking agent for intravenous injection or infusion.
- Rocuronium Inresa 10 mg/ml (10 ml) Neuromuscular blocking agent for intravenous administration.
- Sugammadex Inresa 100 mg/ml (2 ml) Selective relaxant binding agent for reversal of neuromuscular blockade.
- Terlipressin Inresa 1 mg Injektionslösung Injection solution used for treatment of variceal bleeding and hepatorenal syndrome.
- Dexketoprofen Inresa Non-steroidal anti-inflammatory drug (NSAID) for pain relief, administered intravenously after reconstitution and dilution.
- Somatostatin 3 mg Inresa Hormonal preparation administered as a bolus, used for treatment of variceal bleeding and acute pancreatitis.
- InOrpha Flavored suspension vehicle (aromatisiertes Suspensionsvehikel) for formulation of oral solutions and suspensions, used as a proprietary pharmaceutical excipient.
- Einzelimport für Deutsche Apotheken (§73.3 AMG) Individual import service for German pharmacies under §73.3 of the German Medicines Act (AMG), providing access to a diverse range of compliant pharmaceutical products not otherwise available in Germany.
- Licensed Pharmaceutical Distribution Distribution of medical products and pharmaceuticals under license agreements with other pharmaceutical manufacturers, supplied to hospitals and pharmacies.
Companies that use Inresa Drugs
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Inresa Drugs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Inresa Drugs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CuraMED Pharma GmbH (historical)historicalCuraMED Pharma GmbH was sold prior to Inresa's founding in 1993. The founders Bruno C. Wassmer, Gernot Harrant, and Lutz Mothes came from 30 years in the pharmaceutical industry and the sale of CuraMED Pharma GmbH.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Inresa Drugs competitors and assessment
Company assessmentDirect peers
- Rotexmedica GmbH: Rotexmedica is a German-based manufacturer of generic injectable pharmaceuticals. Direct competitor to Inresa in the German hospital injectable generics market with similar product categories and customer base.
- Hameln Pharma GmbH: Hameln Pharma is a German manufacturer of generic injectable pharmaceuticals supplying hospitals globally. Highly comparable to Inresa given the shared focus on sterile injectable generics, GMP manufacturing, and hospital-channel distribution.
- Hikma Pharmaceuticals PLC: Hikma is a multinational generic injectable manufacturer with significant European hospital presence. Directly comparable to Inresa through its focus on sterile injectable generics for institutional customers.
Broad incumbents
- Hexal AG: Hexal is a major German generics manufacturer owned by Sandoz/Novartis. Broad incumbent in the German generics market with deep pharmacy and hospital relationships overlapping Inresa's customer base.
- Fresenius Kabi: Fresenius Kabi is a global leader in hospital generics, infusion therapies, and clinical nutrition. Operates broadly in the same hospital injectable generics space as Inresa with much larger scale and global reach.
- Stada Arzneimittel AG: Stada is one of the largest generic pharmaceutical companies in Germany, offering a broad portfolio including injectables. Larger incumbent serving overlapping German pharmacy and hospital channels.
- B. Braun Melsungen AG: B. Braun is a major German medical and pharmaceutical company with a large hospital injectables and infusion solutions portfolio. Broad incumbent in the same hospital-channel generic injectable space Inresa serves.
- ratiopharm (Teva): ratiopharm is one of Germany's best-known generic pharmaceutical brands, owned by Teva. Serves overlapping pharmacy and hospital channels with a broad generics portfolio.
Emerging players
- Aurobindo Pharma: Aurobindo is a major Indian-headquartered generic pharmaceutical manufacturer with growing injectable generics presence in European markets. Emerging player competing with Inresa in selected injectable categories.
Others
- Aenova Holding GmbH: Aenova is a German-headquartered pharmaceutical contract development and manufacturing organization (CDMO). Adjacent to Inresa's GMP manufacturing operations as a comparable German pharma manufacturing services peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Inresa Drugs social profiles
Digital presenceInresa Drugs compliance and trust
Trust signalCompliance1 record
Inresa Drugs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inresa Drugs leadership team
Management profileNumber of profiles
Profiles2 records
Inresa Drugs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inresa Drugs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inresa Drugs
What does Inresa Drugs do?
Inresa Arzneimittel GmbH manufactures and distributes generic pharmaceutical preparations — primarily injectable and intravenous medications — under its own regulatory approval (manufacturing authorization per §13 AMG) to German hospitals. The company also distributes licensed medical products and pharmaceuticals from other manufacturers, and provides individual import services under §73.3 AMG for German pharmacies requiring access to medicines not otherwise available in Germany.
Is Inresa Drugs a public or private company?
Inresa Drugs is a private company. It is classified as family owned and is currently operating.
When was Inresa Drugs founded?
Inresa Drugs was founded in 1993. It employs 11 to 50 people.
Where is Inresa Drugs based?
Inresa Drugs is headquartered in Freiburg Im Breisgau, Germany, in the Europe region.
How does Inresa Drugs make money?
Three revenue lines are on record. Generic pharmaceutical sales are the primary driver. The others are licensed product distribution and single import services (§73.3 AMG).
Who are Inresa Drugs's main competitors?
Direct peers on record are Rotexmedica GmbH, Hameln Pharma GmbH and Hikma Pharmaceuticals PLC. Broad incumbents are Hexal AG, Fresenius Kabi, Stada Arzneimittel AG, B. Braun Melsungen AG and ratiopharm (Teva). Aurobindo Pharma is listed as an emerging player. Aenova Holding GmbH is listed as an others.
Does Inresa Drugs have an API?
No public API is recorded for Inresa Drugs.
What industry is Inresa Drugs in?
Inresa Drugs's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAC, Sterile Injectable Generics, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.